Skip to content

Study of Acid Peel and Laser for the Treatment of Melasma

A Randomized, Rater-blinded, Split-face Comparison of the Efficacy of 30 % Salicylic Acid Peel vs. Q-switched Nd:Yag Laser for the Treatment of Melasma.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00467233
Enrollment
15
Registered
2007-04-30
Start date
2007-05-31
Completion date
2009-06-30
Last updated
2021-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma

Brief summary

The objective of this study is to evaluate laser treatment and acid peel for the treatment of melasma.

Detailed description

The purpose of this study is to evaluate the safety and efficacy of laser treatment and acid peel for the treatment of melasma.

Interventions

PROCEDURELaser Treatment

Laser treatment to half of the face at each study visit

PROCEDUREAcid Peel

Acid peel to half of the face at each study visit

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of melasma lesion measuring at least 4 square centimeters. * Age 18-75 years. * Good health. * Willingness and ability to understand and provide informed consent for participation in the study. * Ability to communicate with the investigator. * Must be willing to forgo other treatment options for melasma during the course of the study.

Exclusion criteria

* Inability to understand the protocol or to give informed consent. * Mental illness. * Under 18 years of age and over 75 years of age. * Laser treatment in the last 6 months before enrollment. * Isotretinoin within the past year. * Lidocaine allergy. * History of herpes simplex viral infection. * Concurrent active disease to facial area (i.e acne). * Bleeding disorder. * History of abnormal wound healing. * History of abnormal scarring.

Design outcomes

Primary

MeasureTime frame
MASI20 weeks

Secondary

MeasureTime frame
Safety20 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026